BioDuro-Sundia, a drug discovery and development services company, has appointed Haijun Dong, Ph.D., as Chief Executive Officer.
 
Dong replaces Cyrus K. Mirsaidi, who most recently led the company through its 2020 integration, establishing BioDuro-Sundia as a leading CRDMO in the industry, with more than 2,000 employees and operations in seven cities across China and the U.S.
 
The executive team, now led by Dong, will continue to support all aspects of drug discovery, development, and manufacturing of drug substance and drug product.
 
“Our leaders and investors have executed a roadmap of successful growth for BioDuro-Sundia that has now created a natural point for the company to transition leadership. We are very fortunate to have someone of Haijun’s pedigree and vision lead our company into the next phase of that growth—both organic and inorganic,” said David Preston, Chairman of the Board, BioDuro-Sundia.
 
BioDuro-Sundia recently expanded with two new sites in China—an R&D base in Wuxi City and a manufacturing center in Bengbu—that add capacity for more than 1,000 new employees.
 
Dong has served as General Manager & CEO in China for more than 10 years, with experience in large multinational companies, including Roche and Eli Lilly. Dong has a track record of excellence in building and managing companies and business units, and delivering market-leading results.